The inadequate lengthening of telomeres by telomerase allows for mutations to occur. But after carcinogenesis has occurred, the ongoing action of telomerase in those immortal cells allows for lengthening, thereby obscuring the relationship between median telomere length and cancer risk.
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
